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SYSTEMATIC REVIEW OF DECISION ANALYTIC MODELLING IN ECONOMIC EVALUATIONS OF LOW 





Low back pain (LBP) and sciatica place significant burden upon individuals and healthcare systems, with societal 
costs alone likely to be in excess of £15bn. Two recent systematic reviews for LBP and sciatica identified a shortage 
of modelling studies in both conditions. 
 
Objectives:  
1.  Document existing model-based economic evaluations for treatment and management of both conditions. 
2. Critically appraise current modelling techniques, analytical methods, data inputs, and structure, using narrative 
synthesis. 
3. Identify unresolved methodological problems and gaps in literature. 
 
Methods:  
A systematic literature review was conducted whereby 6512 records were extracted from eleven databases with no 
date limits imposed. Studies were abstracted according to a pre-designed protocol, whereby they must be economic 
evaluations which employed an economic decision model and considered any management approach for LBP and 
sciatica. Study abstraction was performed initially by one reviewer who removed duplicates and screened titles to 
remove irrelevant studies. 133 potential studies for inclusion were then screened independently by other reviewers. 
Consensus was reached between reviewers regarding final inclusion.  
Results:  
 
21 publications of 20 unique models were included in the review, of which five were modelling studies in LBP and 
16 in sciatica. Results revealed a poor standard of modelling in both conditions, particularly regarding modelling 
techniques, analytical methods, and data quality. Specific issues relate to inappropriate representation of both 
conditions in terms of health states, insufficient time horizons, and use of inappropriate utility values.  
Conclusion: 
High quality modelling studies, which reflect modelling best practice, as well as contemporary clinical 








Low back pain (LBP) is a very common symptom experienced by most people at some point in their lives [1]. The 
lifetime prevalence and incidence of LBP are 80–85% [2] and 58-84% [53], respectively. Where back pain is long-
lasting, and continues for more than three months, it is considered chronic. The prevalence of chronic LBP is 11% in 
men and 16% in women [4]. Most of LBP is termed non-specific as rarely a cause can be identified to explain the 
symptoms [1]. National and international clinical practice guidelines for the management of LBP recommend 
conservative interventions such as exercises, pain medication as well as psychological therapies, in addition to 
appropriate advice and patient education about the condition [5].  
Sciatica (also called lumbar spinal radiculopathy or nerve root pain) is one distinct presentation of LBP, 
characterised by pain radiating to the leg and often into the foot and toes. The most common reasons for sciatica are 
compression or irritation of a lumbar spinal nerve root by a prolapsed disc, or tightening of the spinal or lateral 
canal, causing the condition termed spinal stenosis which may also give sciatic type of symptoms [6] [7]. Whilst the 
prevalence of sciatica is much less than that of LBP alone [8], it is considered responsible for much of the indirect 
costs and lost workdays associated with back pain [9] [10]. Whilst the management of non-specific LBP is almost 
exclusively conservative, sciatica management options can potentially include, spinal epidural injections and spinal 
surgery, for patients not improving sufficiently with conservative management [11]. Given the scale of the burden of 
disease, high-quality economic evidence is urgently required to determine cost-effective means of managing both 
conditions.  
Generally, compared with a single within-trial-based analysis, decision analytic models are considered a more 
appropriate tool for conducting economic evaluations of chronic conditions [12]. Two previous systematic reviews 
[11] [13] identified mixed results regarding the cost-effectiveness evidence for treatments for both conditions, as 
well as a shortage of  modelled cost-effectiveness analyses for non-invasive and non-pharmacological treatments for 
LBP [14] [15] and treatments commonly available for sciatica in the UK [16]. This study therefore aims at 
identifying and critically evaluating current modelling techniques in both conditions via narrative synthesis, with the 
aim of probing methodological issues and gaps in literature.  
2. Methods 
 
2.1 Study identification and selection 
A protocol was developed using the PRISMA-P checklist (http://www.prisma-
statement.org/Extensions/Protocols.aspx). The protocol specified that studies would be included if undertaking cost-
effectiveness, cost-consequence, cost-benefit, or cost-utility analyses. Studies could consider any treatment or 
management approach for patients with LBP or sciatica. Reviews would be included if the publication also 
contained an economic model. This review excluded economic evaluations which did not include decision analytic 
modelling, studies which did not fully report methods, in this case conference proceedings and abstracts, and non-
English language studies.  
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Articles were identified using database searches, with studies subsequently identified by reference searching also 
considered. The following databases were searched: MEDLINE, EMBASE, PsychINFO, CINAHL, AMED, 
EconLit, Cochrane DARE and CDSR, HTA, NHS EED, and Web of Science.  
In developing the search strategy, JH produced an initial draft strategy where economic terms were based upon a 
strategy developed by the National Health Service (NHS) Centre for Reviews and Dissemination at the University of 
York. Clinical terms reflected strategies taken by other systematic reviews of economic evaluations in LBP and 
sciatica [11] [13]. Terms used in papers known a priori to require inclusion were also used. The strategy was 
subsequently refined by the co-authors, a copy of the search strategy for MEDLINE is included in online appendix 
1. Database searching took place during January 2017. The review was subsequently updated in February 2019.  
2.2 Data selection and extraction  
 
Figure 1 details the selection process. 6512 records were imported into Endnote, of which 1556 were duplicates. A 
two-stage exclusion process was employed. Of the 4956 unique studies, 4823 were excluded in accordance with the 
protocol exclusion criteria, by first reviewer (JH). 3762 studies were excluded because they did not reflect the 
clinical area, 877 were not economic evaluations with economic model, 175 were abstracts, and 9 conference 
publication. 10% (or 400) of these excluded studies were independently checked by one other reviewer (SJ).  The 
133 titles that were considered potentially relevant were then subdivided into “included” and “possible” by first 
reviewer (JH). A second reviewer (SJ) checked the suitability of “included” studies, whilst all “possible”’ studies 
were independently reviewed by all four other reviewers (SJ, KK, RaO and ReO) for relevance. In Figure 1, 
publications deemed “clinically irrelevant” were studies that the first two authors (JH) and (SJ) were not able to 
determine were sciatica or non-specific LBP, these were excluded following further consultation with the clinician 
on the team (KK) regarding whether or not the various conditions described in the studies, constituted a diagnosis of 
sciatica or non-specific LBP. Having reviewed all of the possible studies independently, the five authors (SJ, KK, 
RaO, ReO, and JH) then reached consensus regarding inclusion of the final 20 studies, and one additional study 
(which was referenced in one of the original 20) was also added.  
Data was extracted in accordance with pre-specified criteria detailed in the study protocol.  
3. Results  
3.1 Overview of studies  
 
Table 1 provides an overview of studies included in this review. Studies were classified according to whether 
patients had LBP or sciatica, as each condition potentially requires a different modelling approach. We further 
subdivided sciatica studies according to whether they contained a non-surgical comparator, as modelling studies 
solely for surgical treatments should require a unique structure with model time horizon beginning at the point the 
patient undergoes surgery.   
Five studies were included that evaluated the cost-effectiveness of treatments or management of LBP. Of the fifteen 
that focused on sciatica, nine studies (eight unique models) considered at least one non-surgical treatment, and seven 
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described solely surgical treatments for sciatica. A variety of interventions were considered, with analyses 
conducted across various perspectives. Nearly all included studies were published after 2010 (n = 18). Half were 
conducted in the U.S (n = 11), and the remainder were mostly from developed countries (n=9).  
3.2 Model Design and Structure 
 
3.2.1 Model type  
 
Table 2 summarises the characteristics of model design and structure. Most studies with a determinable structure (n 
= 19) used a Markov model (n = 13) or decision tree (n=4), with two using a decision tree prior to their Markov 
model.  
3.2.2 Time horizon, cycle length and discounting 
 
A variety of time horizons were employed in both conditions. 
For LBP models, horizons were as short as one episode of pain [17] to as long as lifetime [18] [19].  Time horizon 
was associated with model type, with the decision trees modelling the short-term horizons [17] [15] and Markov 
models employed for the longer-term horizons [14] [18] [19]. In terms of cycle lengths, the three Markov models 
which stated their cycle length, all used a cycle length of three months [14] [18] [19]. All studies over year in 
duration ought to discount according to national guidelines [35], and all LBP studies did so appropriately. 
For the sciatica models which included a non-surgical comparator, models were as short as twelve months [20] [11] 
[21] and long as ten years [50]. Markov models were employed to perform the analyses in the longer-term horizons 
[16] [25] [50].  Three months was the most common choice of cycle length, with two models employing such a 
length [16] [24]. All models with time horizon over 12-months discounted appropriately, aside from one which 
explicitly ruled out discounting, incorrectly [23].  
The sciatica models which included only surgical options generally modelled longer time horizons, with the shortest 
being two years [31], and longest models including horizons of ten years [26] [27]. However, many of the cycle 
lengths used in these models were unclear. Of those models using time horizon over 12-months, one explicitly ruled 
out discounting, incorrectly, on the basis their time horizon was 2 years [31]. In three studies it was unclear whether 
discounting was included, or what the time horizon to determine the need to discount [32] [29] [30].  
3.2.3 Health states  
 
Two LBP models based their model structure upon treatment success [15] [17], whilst Kim et al. [14] used states 
reflecting temporal classification of LBP, e.g based upon episode duration. Both Wielage et al. [18] [19] 
publications used states consistent with the model’s interest in pharmacological treatment. Six of the non-surgical 
sciatica treatment models with identifiable structure used “treatment success” to structure their models, all models 
also included symptom recurrence or second treatment or reoperation. Tapp et al. [50] used a simple four state alive 
(post-surgery)/dead model, with the addition of complication and surgical states. Fitzsimmons et al. [21] is an exact 
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replica of a model in a monograph by Lewis et al. [11], which attempted to replicate the treatment pathway for 
sciatica patients in the UK by using a triple stepped treatment pathway. Igarashi et al. [20] was the only model in the 
review which explicitly used health states directly reflective of pain severity, using mild or no pain, moderate, and 
severe pain.  
Many of the surgical sciatica treatment models did not clearly report model structure and methodology [26] [28] 
[32] and one [29] used a simplistic structure. Of the remaining three state transition models, two [30] [31] structured 
their Markov model around treatment success. Meanwhile the simple four-state structure used by Kim et al. [27] 
enabled the representation of many events a surgical patient may experience, including the possibility that a patient 
may not choose a re-operation despite worsening of symptoms.  
3.3 Parameter sources and methods of derivation  
 
Whilst the origins and methods of derivation for treatment efficacies and recurrence rates were of reasonable quality, 
and therefore are not discussed further, there were particular concerns over the derivation of utility values, as well as 
resource use estimates.  
3.3.1 Parameter sources for utility values 
 
Table 3 summarises the sources, as well as the methods, used to calculate model parameters. Wielage et al. [18] [19] 
obtained their utility scores from meta-analysis, Norton et al. [15] and Kim et al. [14] both used utility values from 
adequately sized samples.  However, the utility values for both the non-surgical treatment models for sciatica [11] 
[21] [23] [22] [24] and the solely surgical models [28] [31], were commonly derived from small trials with below 
150 participants in total. 
Both classes of sciatica models had problems with the use of utility values. Launois et al. [16] do not report anything 
about the origin of their values other than they were derived from a “patient survey”. Three studies in the review 
made use of the utility values for “severe LBP” patients in the Beaver Dam Health Outcomes study [34]. One such 
study Koenig et al. [25] state they used utility values for patients with herniated intervertebral disc from a previous 
economic evaluation [33] of lumbar discectomy for treatment of herniated intervertebral disc. However, in their 
original analysis [33] the authors stated they had used utility values for “severe LBP” from the Beaver Dam study 
[34], however Koenig did not state they were for severe LBP. 
Two of the surgical treatment models [30] [26] using the utility values for “severe LBP” patients from the Beaver 
Dam study, used them for patients with lumbar spinal stenosis and spondylolisthesis. Bydon et al. [30] failed to 
acknowledge that the utility values were not for their target population. Moreover, as is explained in section 3.3.2, 
the latter two studies [26] [30] use unusually high utility values for symptom resolution. This is because they have 
used the utility values for individuals in perfect health in the Beaver Dam study [34]. 
Furthermore, the utility values used by  Lewis et al. [11] and Fitzsimmons et al. [21] for “successful treatment” is 
actually the utility value achieved by early surgery in the van den Houdt et al. [47] study, which both papers [11] 
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[21] then apply for successes of all interventions in the model. Moreover, the utility value for “treatment failure” 
used by both [11] [21] represents the baseline utility in one randomised controlled trial (RCT).  
Another study made an erroneous calculation [22] - reporting a 24-month QALY gain of 0.252 for ESI in their Table 
3, comprised supposedly of 12 2-monthly QALY gains of 0.021, this is difficult to spot because they write (12 x 
0.21) instead of what they presumably mean (12 x 0.021). However the calculation is incorrect aside from type 
error, the original source for the 0.021 QALY gain, clearly state, the gain is over 3 months [48].  
3.3.2 Utility Values 
Table 4 presents the actual utility values used as inputs in the studies in this review. There were some differences in 
the utility values used in the LBP studies, likely partly explained by their specific population. The meta-analyses of 
chronic LBP patients who were prescribed pharmacological treatments, showed that chronic LBP patients had utility 
values of between 0.7282 (Pregabalin) and 0.7688 (Naproxen) [18] [19]. Meanwhile, the other studies suggested 
lower values; Kim et al. [14] used 0.62 and 0.65 for chronic LBP patients on usual care and acupuncture, 
respectively, although acute LBP (0.85) and “well” states (0.96) were considerably higher; and Norton et al. [15] 
used much lower scores, with an improving chronic LBP patient having utility of 0.640, and a non-improver having 
utility of 0.59.  
 There was some consistency across some of the sciatica decision models which incorporated conservative care and 
used utility values independent of treatment. Igarashi et al. [20] report that a sciatica patient without pain would 
have a utility of 0.867, whilst “severe pain” would be 0.611, somewhat consistent with the scores used by Koenig et 
al. [25] for treatment of herniated intervertebral disc.  Both studies are consistent also with the value used for 
“improvement” in sciatica patients by Lewis et al. [11] & Fitzsimmons et al. [21], although the “non-improvement” 
score in the latter is lower than other scores at 0.37.  
Skidmore et al. [23] use utility scores for each treatment which are weighted averages of both improvers and non-
improvers on each treatment, and are weighted also for likelihood and disutility of adverse events. Their weighted 
average for conservative care (which has only a 4.8% success rate), is a utility value of between 0.61 and 0.65 over 
the duration of the model. Given that non-improvers are the predominant constituent of the conservative care group, 
this value is consistent with the utilities of the other non-improving patients in the prior four studies discussed. The 
values used by Tapp et al. [50] for post –surgery, which represents a patient after surgery without complications, is 
slightly higher at 0.77, although the values also account for the disutility associated with complications and 
recurrence separately.  
For the solely surgical studies, the two studies which used the Beaver Dam Study, applied a utility value of 0.79, for 
symptomatic spinal stenosis patients in one study [26] and for lumbar spondylolisthesis patients with a negative 
outcome in another [30]. Both studies also used a utility value of 0.97 for having a positive outcome. These values 
are far higher than the two other studies to use ”improve” / “non-improve” to differentiate patients. For patients with 
with lumbar spondylolisthesis;  Kim et al. [27] used 0.74 for an improvement with fusion and no-fusion, compared 
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to non-improvement of 0.50 and 0.54 respectively, baseline patients had a utility value of 0.58 [27]; and Schmier et 
al. [28] used a value for “clinical success” of 0.692, whilst “failure” had utility 0.552 and “worsening pain” 0.599.  
Parkinson et al. [31] used much lower baseline pre-operation utilities of 0.42 and 0.36, although possibly explained 
by their specific population, patients with sciatica who had failed conservative treatment. After two years their 
patients who had AIDR had average utility of 0.67 and patients who had fusion had utility of 0.69. These scores are 
similar to the patients undergoing spinal fusion to whom Vertuani [32] assigned utilities of 0.72 after two years 
following minimally invasive surgery and 0.68 following open surgery.  
3.3.3 Parameter sources for resource use 
A variety of methods were used in deriving resource use.   
Of the LBP studies, two studies [14] [15] estimated their resource use using information from trials, both of which 
were pragmatic trials. Lloyd et al. [17] used expert opinion to estimate resource use across the 4-day model time 
horizon. The two studies by Wielage et al. [18] [19] used a combination of expert opinion, databses and published 
literature. Of the non-surgical sciatica models, heavy reliance was made upon experts in order to derive resource use  
[11] [20] [23] [21]. Launois et al. [16] obtained resource use from the uncited survey and unreferenced material. 
Koenig et al. [25] relied primarily upon the SPORT trial [70], with surgery frequency derived from a recent analysis 
of the Medicare claims database [71]. Parker et al. [24] used data from a telephone interview to obtain follow-up 
costs. Tapp et al. [50]did manage to utilised the Medicare Provider Analysis and Review database for surgery, 
complication and re-operation costs, although the value of their analysis was diminished somewhat by their 
assumption that the cost of conservative care, as well as supplementary care for surgical patients, was zero. The 
solely surgical modelling publications made more use of administrative databases, with two studies deriving 
resource use almost entirely from hospital databases [26] [27], and two [28] [31] using databases in conjunction with 
published literature and expert opinion. Bydon et al. [30] used the same 137 patient institutional series they used to 
derive all their other parameters, which allowed the precise calculation of costs of surgery and inpatient costs at their 
institution. Vertuani et al. [32] performed a literature review and meta-analysis to identify resource usage. Finally, 
Yaghoubi et al. [29] did not identify resource use, but instead opted to obtain costs directly from published literature 
supplemented by patient feedback.  
3.3.4 Methods and parameter sources for calculating societal costs  
Six models attempted some analysis from the societal perspective. The most detailed attempt came from Igarashi et 
al. [20] who based their analysis on the Work Productivity and Activity Impairment (WPAI) questionnaire adapted 
for LBP, and includes losses owing to absenteeism and presenteeism. Three studies employed variants of the human 
capital approach to estimate productivity losses occurring due to productivity losses [14] [11] [24]. One study [23] 
claimed that “Indirect costs of lost productivity and intangible costs of pain and suffering related to treatment 
morbidity are not estimated directly but instead are implicitly incorporated in the utility values” 
3.4 Summary of cost-effectiveness results 
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The results can be summarised as follows. For episodes of acute LBP, heat wrap dominates paracetamol and 
ibuprofen [17]. In Korea, acupuncture appears to be a cost-effective means of managing chronic LBP, relative to 
routine care [14].  Duloxetine is suggested to be a cost-effective means of managing chronic LBP pain in the U.S 
and Canada, and dominates most other pharmacological comparators, although it is unclear whether or not it is cost-
effective relative to Naproxen (although there are further author correspondences regarding the modelling of 
tapentadol) [18] [19].  CBT (Cognitive Behavioural Therapy) is cost-effective relative to educational materials in 
treating chronic LBP in Canada [15]. Societal analyses considerably decreased the cost per QALY for the most 
effective treatments (i.e. made an intervention more cost-effective) [14] [19].   
In sciatica, a comparison of two pharmacological approaches for managing Japanese patients who had severe LBP 
pain alongside a neuropathic component, showed that pregabalin was cost-effective compared to usual care 
treatment with standard analgesia [20]. All other sciatica studies considered some form of surgery as a comparator, 
with the length of time that patients spend receiving conservative care, and ordering of treatments, seeming to 
determine the cost-effectiveness of surgery. For example, in a review of over 100 different potential treatment 
combinations for patients presenting with sciatica, Lewis et al. [11] and Fitzsimmons et al. [21] show that in the UK, 
stepped care approaches based on initial treatment with non-opioids are the most cost-effective, whilst referring 
patients who fail an initial treatment to surgery is unlikely to be cost-effective. However, evidence from the U.S 
suggests that surgery after one course of failed treatment or extended duration of symptoms could be cost-effective. 
In one study of patients with moderate to severe lumbar spinal stenosis (LSS), who failed conservative therapy, 
minimally invasive lumbar decompression maybe cost-effective ($43, 760 per QALY) relative to standard non-
surgical treatment [22]. Compared with ongoing conservative care, Skidmore et al. [23] show that for moderately 
impaired patients with LSS, decompression surgery using a spacer is cost-effective relative to non-surgical care and 
dominates laminectomy. Amongst LSS patients complete six months of conservative treatment without 
improvement, Parker et al. [24] show that the minimally invasive interspinous spacer and decompression surgery are 
highly cost-effective relative to conservative care at $16,300 per QALY and $15,200 per QALY respectively. Tapp 
et al. [50] show that over ten years, for patients with LSS and no previous surgery, minimally invasive procedures 
using a spacer and decompression are cost-effective relative to usual care at $25,000 per QALY and $30,874 per 
QALY respectively. Although the evidence on surgery for patients with lumbar disc herniation suffering functional 
limitations, suggests discectomy may not be cost-effective relative to non-surgical care ($52,416 per QALY), 
although inclusion of societal costs decreases the incremental cost effectiveness ratio (ICER) to $35,146 per QALY 
[25] 
Of the papers which evaluate solely surgical techniques, three U.S studies suggest that various spinal fusion 
techniques are not cost-effective across different populations and relative to other surgical techniques without 
fusion, e.g. laminectomy without fusion [26], lumbar decompression without fusion [27] and the Coflex® 
interlaminar stabilization following decompressive laminotomy [28]. Furthermore, evidence from Iran supports the 
cost-effectiveness of the Coflex® relative to the X-Stop and laminectomy [29]. In studies evaluating only means of 
performing fusions, for US patients with degenerative sponydylolisthesis, interbody fusions were found cost-
effective relative to non-interbody fusion, at $9,883.97 per QALY [30]. Amongst Australian patients with radicular 
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pain who failed conservative treatment, posterolateral fusion was deemed to be the most cost-effective surgical 
approach for lumbar fusion or artificial intervertebral disc replacement (AIDR) [31].  Finally, in the UK & Italy, 
minimally invasive surgery dominated open surgery for one- or two-level lumbar spinal fusion in the treatment of 
degenerative lumbar spinal conditions [32].  
 Discussion  
4.1 Statement of principal findings 
 
4.1.1 LBP models 
Structure 
 
Choice of time horizon should be justified, and ought to reflect important differences between comparators and not 
be driven by data availability [35] [36] [37] [38]. The two LBP models by Wielage et al. [18] [19] were the only 
ones to use the life-time horizon, possibly because data was readily available for their specific decision problem. For 
the other three studies, the use of medium-term time horizons could be permissible given that many treatments for 
LBP do not provide a long-term treatment effect.   
In terms of model type, four LBP models used Markov state transitions suggesting that these authors considered this 
approach appropriate for modelling LBP.  However, in situations in which an early event or patient characteristic 
determines future patient pathways, and the number of health states required might be unwieldy, individual level 
microsimulation methods should be considered[36].  
Health states should adequately reflect the condition specific health processes [36]. Upon this basis, the three-state 
approach used by Norton et al. [15], ”improved”, ”not improved” and ”dead”, might be considered an 
oversimplification. Whilst using “improved” and “not-improved” will, to some degree, always incorporate the pain 
associated with each treatment; unless utility values are always collected separately for each treatment, interventions 
which deliver higher rates of long-term improvement at a lower level of utility will be advantaged by using states 
reflecting “improvement”.  
For LBP, we advocate an approach starting from the structure used by Kim et al. [14], who chose states reflecting a 
temporal classification of LBP - ”acute LBP”, ”chronic LBP”, “well”, and “dead”. However, the internal validity of 
their particular model is limited by the structural assumption that one recurrence of back pain in the “well” state can 
move the patient into “chronic LBP”. This leads to the possibility a patient with only two episodes of LBP across 5 
years would be considered to have “chronic LBP”. Nonetheless, the modelling of degrees of symptoms is preferred 
over a dichotomy, as it is likely to produce results which better reflect the patient experience. It is also worth noting 
that it is likely that there is heterogeneity in pain severity within temporal classifications.  
Current research evidence suggests that a potentially more appropriate categorisation of patients with LBP could 
reflect pain severity as well as the rate of recurrence [39]. Dunn et al. [39] for example, show that pain level after 
one year is predictive of pain level at seven years, and patients are categorised in three groups, according to 
persistence and severity, “no or occasional pain”, “persistent mild pain”, and “persistent severe pain”, with a fourth 
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category used for those who show no consistent pattern. Ultimately, model structure and health state selection 
should involve consultation with subject experts and stakeholders [36]. Whilst experts were clearly involved in the 
construction of these models, none of the studies clearly justified, or discussed issues related to their model 
structure. The lack of discussion around choice of health states, or model choice and time horizon, is problematic for 
improving the representation of both conditions in model form, as such subjective components of the modelling 
process should be predicated upon a clear understanding and subsequent critique of, the principles upon which such 
decisions are made.   
Data 
High-quality information on resource use in LBP patients does not seem to be available. Both the Wielage et al. [18] 
[19] papers had to rely mainly upon expert opinion in order to derive resource usage, with two other studies relying 
upon trial-based estimates [14] [15]. With regard to the utility values for the LBP models, these were obtained in 
accordance with best practice [14] [15] [18] [19].  
Four LBP models extrapolated over a longer period than their data allowed, although only Wielage et al. [18] [19] 
attempted lifetime extrapolation. Having evidence available to them, both studies modelled across the lifetime by 
adjusting the adverse event (AE) profiles according to age-dependent relative risks and used age-dependent utility 
values directly obtained from available literature. However, often in decision problems relating to LBP, evidence of 
long-term treatment effect is likely to be unavailable because trials commonly span only across one year of patient 
observation.  Norton et al. [15] and Kim et al. [14] show how an incomplete evidence base can still be extrapolated 
in a decision analytic model by using assumptions and expert opinion in addition to literature. Both studies defined 
their health states independently of treatment and established utility values for those specific health states, therefore 
requiring only information on the long-term movement of patients between health states. Lacking data on long-term 
treatment efficacy, Norton et al. [15] assumed a gradual loss in efficacy (resolution of symptoms) over time of 20% 
per annum. Similarly, Kim et al. [14] extrapolate short-term treatment efficacy assuming short-term relative risks 
between the treatment arms remained constant over time.  
Given that parameter behaviour over time, such as the long-term treatment effect, often represents the largest source 
of uncertainty within a model [40], studies performing extrapolation should be expected to undertake rigorous 
examination of temporal uncertainty [35]. However, none of the five LBP models really addressed temporal 
uncertainty, despite the importance of extrapolation assumptions used by Norton et al. [15] and Kim et al. [14]. 
Consequently, the reader is left without an understanding of how the uncertainty over the long-term treatment effect 
could impact the cost-effectiveness of these treatments for LBP.  
4.1.2 Sciatica non-surgical treatment models 
Structure  
For this group of models, three studies used Markov modelling and three decision trees. However, given that surgery 
was a comparator in all models, and would be expected to improve long-term outcomes for sciatica patients, short 
time horizons modelled within a decision tree may seem unsuitable in this condition. The use of individual sampling 
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models (ISM) could be of real value in this condition, given that candidacy for surgery is likely to be event-
dependent, e.g. having a failed previous treatment, and/or time spent in severe pain.  
Treatment guidelines for sciatica in the UK follow a stepped pathway, in that patients can receive more invasive 
treatments dependent upon prior treatment failures. Most models did allow between one and three stepped treatment 
failures before they allow surgery to take place e.g. [11] [16] [21] [24] [25]. Lewis et al. [11] and Fitzsimmons et al. 
[21] presented not only the stepped nature of the treatment pathway but provided 100 different treatment 
combinations. Yet, the complexity of the representation of the treatment pathway appears in contradiction to the 
simplicity of the estimates used for the utility values, which in turn may limit the validity of the study results.  
Whilst there is clearly a need to represent the stepped pathway when modelling a pre-surgical period of the 
treatment pathway, it is doubtful that a typical model should consider all combinations of possible treatments unless 
that is the specific goal of the analysis, as was the case in the Lewis et al. [11] and Fitzsimmons et al. [21] 
publications.   
If the aim of the analysis is to compare an intervention with usual care, then it might be more efficient to have a 
comparator which represents common/usual practice. Indeed, most models only compared 2 or 3 treatment options, 
one of which included conservative care. Two studies [23] [24] used a comparator which reflected a specific 
combination of usual care treatments based upon an observed combination of treatments.  For example, Skidmore et 
al. [23] use “conservative care” as their comparator, defined as at least one epidural steroid injection, supplemented 
by nonsteroidal anti-inflammatory medication, oral steroids, analgesics, physical therapy, or spinal manipulation 
therapy. Their data on treatment was derived from a trial where patients received usual care as considered 
appropriate for the individual patient. Finally, Parker al. [24] refer to conservative care, as physical therapy, pain 
medications (NSAIDs, mild opioids), and epidural steroid injections, as guided by clinical judgment of the treating 
physician. Their data were derived from analysis of institutional registry data, and trial data.  
The approach used by The Institute for Clinical and Economic Review [46] in it’s model of treatments for lumbar 
disc herniation, whilst grey literature and not included in the review, is nonetheless worthy of consideration. It uses a 
Markov model which allows patients to continue on some specific combination of usual care treatments (identified 
by systematic review), and also allows a specific proportion of the cohort to move into receive a discectomy. Upon 
receiving a surgical procedure, patients can then improve, receive a second reoperation or suffer a complication.  
Assuming that the model requires the entire pathway to be modelled, we would advocate taking the best of these 
approaches, by representing the stepped nature of the treatment pathway by initially defining usual care as the 
treatment combination which evidence shows that sciatica patients initially receive.  If the model took the form of an 
ISM or a discrete event simulation, it would be possible to use tracker variables to track the length of time a patient 
remained symptomatic, and/or receiving the described initial usual care. After some defined period of non-
improvement, a patient could either become eligible for a more intense usual care treatment option (a second-step), 
and/or upon failure of that second treatment become eligible for surgery. As well as time spent in receipt of usual 
care, patient’s candidacy for surgery could also be a function of the unique characteristics of that patient, although 
the degree of complexity will be limited by available data. 
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With regards to the choice of the states, similarly to the LBP models, all but one [20] used states relating to 
treatment success. The use of health states such as "improved" and "not improved" are perhaps more appropriate in 
models for sciatica in which perhaps interventions such as spinal injections and/or surgery might be expected to 
provide a more pronounced and sustained treatment response, on average, when compared to treatment effects for 
non-specific LBP..  But, as noted above, with respect to modelling, if such states are used, this will necessitate that 
utility values are collected for each intervention, as some interventions could deliver their improvement at very 
different utility levels. A related issue is that all of the studies use different definitions of success or improvement, 
making comparison between studies difficult.  
Guidance suggests that where states reflect the treatment pathway effect, this ought to be justified and alternative 
methods of doing so explored in sensitivity analysis [40], however none of the studies  justified their approach or 
explored alternate methods.  The only model in this review to provide health states based upon pain severity [20] 
provides a starting place for how pain severity could also be used to conceptualise health states for sciatica. No 
pain/mild pain, moderate pain, and severe pain are used as states. Nonetheless, the inability to move between states 
during 3-11 months and the model’s short 12-month timeframe, somewhat diminishes its potential as an example of 
best practice, if it is accepted that the analytical framework ought to be over a longer-period. Whilst “improved” or 
“success” models are likely to be conceptually linked with pain severity to some degree, the potential implications 
for cost-effectiveness estimates of using an “improved” or “success” based model over one based upon pain states 
could be one area of future research.  
 Data   
Only 3 of 9 models attempted extrapolation. Launois et al. [16] used literature to extend parameters over the longer-
term, whilst Igarashi et al. [20] simply extrapolated 8 week pain scores to 52 weeks, citing a previous study as 
justification.  Tapp et al. [50] extrapolated from 4 years to 10 years, by determining the long-term rate of re-
operation for decompression from the literature, and lacking data on long-term reoperation with the spacer, assumed 
the rate  was identical to decompression. They also use the same utility values over time, and assume that 
complication rates are the same regardless of first surgery or re-operation. Their cost-estimates are unlikely to be 
accurate however, given that they do not include costs of other treatments aside from surgery and conservative care 
and post-surgical care carry zero cost.  
That only 3 of 9 non-surgical sciatica models attempted extrapolation, was typically justified by the claims of 
Fitzsimmons et al. [21] of a “lack of evidence regarding relapse and recurrence rates” making “it difficult to extend 
the analysis beyond this time period”. It is certainly the case that where estimates extend well beyond known 
available data, the accuracy of the estimates may be questionable. Yet as stated above, best practice guidelines in 
decision analytic modelling state that data availability should not define the time horizon of the model [35].  The 
apprehension regarding extrapolation is perhaps somewhat unfounded given the two of the LBP studies above [14] 
[15], and one sciatica model [50] made simple assumptions regarding the long-term treatment effect. Moreover, 
there are many techniques to infer values for unobserved model parameters [40]. For example, Mahon [40] 
advocates fitting parametric functions through statistical methods, and/or using expert opinion to derive some 
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probabilistic assessment of the likelihood a parameter function takes a certain shape. Nothing approaching this level 
of sophistication was attempted in any of these papers in this review.  
Given the productivity costs associated with both LBP and particularly sciatica, it might be expected to see more 
analyses performed from the societal perspective, at least as a secondary evaluation. Yet as Table 1 showed, and 
Table 3a details, in this review only six models performed some form of societal analysis, which were of varying 
rigour. The most detailed method [20] used the established methodology of the WPAI scale [41], a validated method 
to assess lost productivity that assesses the losses due to both absenteeism and presenteeism. Although for a full 
societal analysis, other non-medical costs should be also included, as per Kim et al. [14] who included costs of 
visiting, treatment times and traffic expenses.  
The utility values used in this class of models reflect to some degree the lack of availability of utility data for 
sciatica patients. The methods used by Lewis et al. [11] and Fitzsimmons et al. [21] to calculate utility values show 
why it is not necessarily advisable to have values based upon the success or failure of a treatment because an 
appropriate analysis would require many unique utility values. As this information is clearly not available, the 
authors used the same utility values for “success” or “failure” of all the treatments in their study, which would bias 
against those treatments which delivered higher utility gains where successful and/or treatments which minimise 
utility losses where they fail. Moreover, whilst their value of 0.83 for treatment improvement seems consistent with 
other studies [20] [25], their “non-improvement” score of 0.37 is significantly lower than values used for non-
improvement in most other studies in this review. This highlights the need for consistent health state selection and 
definition, in the models. Admittedly, the authors of both studies [11] [21] acknowledged the problems with utility 
values which they attempted to address using  alternate scenarios in sensitivity analyses, although results of these 
analyses were not presented.  
There were also concerns in relation to the derivation of resource use estimates, which ought to originate from real 
clinical practice instead of clinical trials [42]. Yet, for the sciatica non-surgical treatments, only Tapp et al. [50] 
obtained some of their cost estimates from a database reflecting actual patient healthcare usage, and half had to rely 
on expert opinion, suggesting a problem with availability of high-quality resource use information. This is 
understandable given how challenging it can be to identify and attribute visits when conditions may be mentioned 
only incidentally.  
4.1.3 Sciatica surgical treatment models 
 
Structure  
Whilst it is commendable that the time horizons considered by the surgical intervention models were longer than the 
non-surgical models, albeit this group of models was replete with methodological problems. Of the models with 
identifiable structure, 5 out of 7 were Markov models, which are recommended for decision problems, such as 
modelling surgical procedures, where model horizon is longer and/or model contains time varying transition 
probabilities [44]. In the case of models which begin from a surgical process, a Markov model is sufficient, provided 
they allow the possibility of future re-operation following recurrence of symptoms. The need for an ISM is less 
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pressing than in the case of a sciatica model including a pre-operative period, although allowing a risk of recurrence 
to be dependent upon individual characteristics would offer the model more flexibility.  
Given that all comparators in this group were surgical procedures and did not feature conservative care, health states 
generally are reflective of the “success” or “failure” of surgery rather than health specific processes. As noted above, 
there is still a need amongst these models to use consistent health states and definitions for comparability. The 
structure used by Kim et al. [27] could provide a basic template for developing a more sophisticated model structure. 
Their model health states were potentially more appropriate because of the use of states such as “well”, “unwell”, or 
“return of symptoms”, which partially reflect the condition specific health processes, and captured all important 
events for  sciatica patients, e.g. relapse, reoperation (including the flexibility of choosing whether or not to re-
operate), clinical worsening and improvement, and general and perioperative death.  
Data 
The Kim et al. [27] structure can also provide a framework within which to engage in extrapolation processes. Using 
the health states of “well”, “unwell”, or “return of symptoms”, they then derived long-term utility values associated 
with these states, independent of treatment approach, from their one-year observational study. To justify the use of 
these one-year values across ten years, they referenced a study by Weinstein et al. [43] who suggested that utility 
values derived at one year are relatively stable across four years, and then assumed further stability to ten years. 
Although the authors then adjusted the values downwards by 3% per-year to account for clinical deterioration rather 
than present net value. . Where possible, the impact of age upon the utility of the patient population should be 
modelled using available data or a data driven assumption. Regardless, having established their utility values, they 
then required only annual transition probabilities between states for 10 years, which they derived using an 
administrative database study and data from the senior surgical authors practice.  
As with the sciatica non-surgical models, the quality of the utility values was generally poor, as would be expected 
given that they are for similar populations. However, whilst it is to be lauded that attempts were made to derive 
patient- and treatment-specific utilities, small sample sizes [28] [31] and the use of LBP utility values from the 
Beaver Dam study [26] [30] were a common limitation of this group of publications. The use of the Beaver Dam 
values of 0.97 for being symptom free [26] or having a positive outcome [30] and 0.79 for having CLBP are quite 
different to the utility values used in other studies.  
The use of administrative databases in five studies [26] [27] [28] [30] [31] facilitates precise calculation of resources 
associated with each treatment, and therefore offers more confidence in accuracy of the costs associated with these 
surgical procedures. 
4.2 Strengths and weaknesses of the review 
 
This is the first systematic review to identify, document and classify model-based economic evaluations of 
treatments for LBP and sciatica. It is possible that the search criteria may prove restrictive, in that model-based 
economic evaluations faced exclusion if they did not contain both economic and modelling terms. The search 
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strategy may have been improved by including the term “utility”. However, the use of a very broad search strategy 
was employed including “economic” or “model” as standalone terms, with the specific aim of increasing potential 
number of studies. The breadth of these search criteria, as well the variety of databases used, is a key strength of this 
review, and the addition of a single paper identified from reference lists demonstrates that the search was exhaustive.  
4.3 Implications for researchers, clinicians and policymakers 
 
This review identifies flaws, and suggest opportunities, in models evaluating interventions for LBP and sciatica. 
Concerns relating to studies in this review include, not only modelling across inadequate time horizons, but the 
inappropriate use of utility data, calculation errors, a lack of transparency regarding methodologies, and the failure 
to consider the extent to which uncertainty and assumptions limit the applicability and generalizability of the results.  
Overall, the current cost-effectiveness evidence is indicative of the uncertainty around the clinical effectiveness 
evidence on these treatments to-date. Most of the studies included in this review do report on the limitations of 
available effectiveness data in order to populate models. Policymakers’ attention is directed to the sensitivity 
analyses in these studies, which in some cases help with accounting for the uncertainty of model parameters. Longer 
follow-up in trials, and collection of HRQL scores, would help with reducing the uncertainty around long term cost-
effectiveness of treatment.  
In considering the cost-effectiveness results from studies which included a non-surgical comparator, it is evident that 
surgery after the failure of conservative care, could be cost-effective. However, there does not appear to be a 
consensus regarding at what stage surgical procedures might become cost-effective. This could be a potentially 
valuable research priority, alongside factors which influence the cost-effectiveness of surgery following these 
repeated failures of conservative care.  It is also noted that research needs to explore the implications of using 
different health states in both conditions.   
Health economists and modellers developing models in both conditions, also need to be more willing to explore the 
implications of extrapolation of treatment effect over an appropriate time horizon. The thesis by Mahon [40] 
provides a comprehensive review of the methods which can be used to infer parameters where they are unobserved. 
Additionally, guidance is available on how to capture the associated uncertainty relating to extrapolation of 
unobserved treatment parameters in sensitivity analyses.  NICE methods guidance advocate scenario analyses with 
(i) nil treatment effect over the unobserved period; (ii) treatment effect during the unobserved period is set equal to 
the observed period; and (iii) treatment effect diminishes over time [51] 
Future models should pay particular attention to the methodological challenges raised here to help ultimately enable 
more useful comparisons between treatments. But until modellers produce more high-quality modelling studies, 
consistent with modelling guidelines (e.g. [35] [38] [42] [44] [45]), the standard of discourse necessary to stimulate 
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